Alimera Sciences IluvienR Receives FDA Priority Review for the Treatment of Diabetic Macular Edema

ATLANTA, Aug. 30, 2010 GLOBE NEWSWIRE — Alimera Sciences, Inc., Nasdaq:ALIM “Alimera”, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company’s New Drug Application NDA for Iluvien� fluocinolone acetonide intravitreal insert has been accepted for filing and granted Priority Review status by the U.S. [...] http://bit.ly/afrLNx